CCK acts at the vagal afferent CCK1R to mediate postprandial satiety; however, while full agonist drugs of this receptor have stimulated weight reduction in patients, they have not achieved the primary end point of exceeding the effectiveness of acute dieting in clinical trials for obesity (31). Here, CCK is linked to obesity disorder.